Membrane Proteins: The Key Players of a Cancer Cell

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

(2015) Marlies H.G. Langenberg et al.   NEOPLASIA

Near-Infrared pH-Activatable Fluorescent Probes for Imaging Primary and Metastatic Breast Tumors

(2011) Hyeran Lee et al.   BIOCONJUGATE CHEMISTRY

Monitoring response and resistance to treatment in chronic myeloid leukemia

(2011) S. Assouline et al.   Current Oncology

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

(2011) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer

(2010) Jin Hee Maeng et al.   BIOMATERIALS

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma

(2010) Thomas Yau et al.   CANCER

(−)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells

(2010) Masahito Shimizu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

A phase 2 study of vatalanib in metastatic melanoma patients

(2010) Natalie Cook et al.   EUROPEAN JOURNAL OF CANCER

Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia

(2010) Andrew J. Gentles   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab for gastric cancer treatment

(2010) Alicia FC Okines et al.   LANCET

The future of CD20 monoclonal antibody therapy in B-cell malignancies

(2010) Myron S. Czuczman et al.   LEUKEMIA & LYMPHOMA

Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells

(2010) Lara Milane et al.   MOLECULAR PHARMACEUTICS

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells

(2010) P M Das et al.   ONCOGENE

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

(2010) Y Gan et al.   ONCOGENE

Specific Visualization of Glioma Cells in Living Low-Grade Tumor Tissue

(2010) Sven R. Kantelhardt et al.   PLoS One

EGFR Targeted Fluorescence Imaging in Gliomas

(2009) Harish Poptani   ACADEMIC RADIOLOGY

Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors

(2009) Kathleen M. McNeeley et al.   BIOMATERIALS

TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer

(2009) John Mackey et al.   Clinical Breast Cancer

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003

(2008) Peter M. Smith-Jones et al.   NUCLEAR MEDICINE AND BIOLOGY